Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin

Br J Dermatol. 2022 Dec;187(6):1019-1021. doi: 10.1111/bjd.21772. Epub 2022 Aug 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acitretin / adverse effects
  • Anticarcinogenic Agents* / therapeutic use
  • Bexarotene / adverse effects
  • Humans
  • Lymphoma, T-Cell, Cutaneous* / chemically induced
  • Lymphoma, T-Cell, Cutaneous* / drug therapy
  • Retrospective Studies
  • Skin Neoplasms* / chemically induced
  • Skin Neoplasms* / drug therapy
  • Tetrahydronaphthalenes / adverse effects

Substances

  • Bexarotene
  • Acitretin
  • Tetrahydronaphthalenes
  • Anticarcinogenic Agents